Harmony Biosciences (HRMY) FCF Analysis: Dated Runway

FCF Performance Summary

Market Cap: ~$2.12B  |  Enterprise Value: ~$1.31B  |  Price: $36.13 (close of October 23, 2026, from a secondary market-data source). Enterprise value uses $809M of net cash at June 30, 2026 ($962.5M of cash and investments less $154.0M of debt).

Against the two other healthcare names the site has analyzed, Harmony's cash margin is the highest by a wide gap. Pacira Biosciences (PCRX) converted 18.8% of FY2025 revenue to FCF at a 13.1% yield, and GoodRx (GDRX) converted 11.8% at a 7.8% yield. Harmony's 40.1% falls to 29.5% once the 2025 working-capital inflow is removed, which is still well above either comparison. The prices behind those yields were taken on different dates (September 11 for the two earlier posts), so the comparison is directional, not exact.

Cash Generation Quality

FCF ran at 219% of GAAP net income in FY2025 ($347.9M against $158.7M) and 165% of adjusted net income ($211.0M). A ratio that far above 100% for a company with no meaningful capex means something non-cash or timing-related is helping, and three items explain it. Intangibles amortization adds a flat $23.9M a year, which is structural. Stock-based compensation adds $45.0M. The third is a $91.8M working-capital inflow in 2025, driven mostly by accrued expenses that rose from $120.6M to $191.0M. Those accruals started to reverse in Q1 2026, when they fell $40.9M to $150.1M.

Strip out the working-capital swing and FY2025 FCF was about $256M, 121% of adjusted net income. That is the base this analysis carries forward, and it matters because consensus builds on the clean figure: FCF excluding working capital is projected at $303M in FY2026E and $357M in FY2027E, about 18% growth in each year.

Owner earnings are less distorted. SBC was 12.9% of FY2025 FCF, leaving $302.9M after SBC and a 14.3% yield on that basis, so dilution trims the headline without changing the picture. Capital spending is too small to matter, which sends the whole quality question into operating cash flow. FCF is 99.5% to 99.9% of operating cash flow in every year from FY2021 to FY2025. About $35.5M of FY2025 operating cash flow (10%) and $43.7M of FY2024 (20%) sits in lines that the condensed Bloomberg cash flow statement does not itemize. The XBRL operating cash flow totals tie to the Bloomberg figures, but the composition of that residual was not decomposed, and the 10-K cash flow statement is the place to verify it.

FY2022–FY2025 Capital Allocation Breakdown

The percentages sum to slightly over 100% because $22.7M of other inflows is not itemized in the export. The repurchase figure is a residual from the financing section, and XBRL tags $100M of 2023 repurchases, a gap under 5%. A year-by-year split for FY2025 alone is not available from the data set, so the table covers the four years since FY2021. Seventy cents of every FCF dollar stayed on the balance sheet earning about 3% (interest income of $21.9M in 2025), while the diluted share count barely moved, from 59.2M in 2021 to 58.5M in 2025. Buybacks have roughly offset dilution and no more.

The acquisition line deserves a second look. Outflows outside operating cash flow and capex totaled about $271M over FY2021 to FY2025, roughly $54M a year or a quarter of the $1,028M of cumulative FCF. Harmony does a licensing or acquisition deal nearly every year, so treating those costs as optional flatters the run rate. After those outflows, FY2025 FCF was $313.6M. The range for what 2025 left after feeding the pipeline is therefore about $256M to $314M, not $348M.

5-Year FCF Trend Analysis (FY2021–FY2025)

The trajectory is a growth run that paused for a year in 2024 and then jumped, with part of the 2025 jump coming from timing.

  FY2021   $98.3M   ##########
  FY2022  $144.3M   ##############
  FY2023  $219.1M   ######################
  FY2024  $218.7M   ######################
  FY2025  $347.9M   ###################################

  FY2021-FY2025 CAGR: 37.2%  |  3-Yr CAGR (FY2022-FY2025): 34.1%  |  5-Yr Avg: $205.7M
  (each # is roughly $10M)

Trend Narrative

From FY2021 to FY2023, FCF more than doubled from $98.3M to $219.1M while revenue grew from $305.4M to $582.0M. The driver was patient growth on a single product with almost no capital requirement, so each incremental revenue dollar dropped through at a high rate: FCF margin rose from 32.2% to 37.6%. FY2022 net income of $181.5M looks out of step with the $144.3M of FCF that year because it includes an $86M non-cash release of a tax valuation allowance, not cash.

FY2024 is the odd year. Revenue grew 22.8% to $714.7M, yet FCF was flat at $218.7M and the margin fell to 30.6%. Working capital swung from a $35.0M inflow in 2023 to a $7.3M outflow, a $42M turn, and the deferred-tax line moved to negative $29.3M. On the usual reading of that line's sign convention, cash taxes ran above book taxes. Neither effect says anything about demand, but both are reminders that reported FCF moves with timing items even in a business this simple.

FY2025 grew 59.1%, and about $92M of that growth was working capital. Measured without it, FCF rose from $226.0M to $256.1M, a 13% increase, which is a healthier description of the underlying trend. Consensus has FY2026E FCF dipping 14% to $297.8M and recovering to $348.7M in FY2027E. The dip is mostly the working-capital inflow reversing: operating cash flow falls about $50M, net income adds roughly $83M, and working capital swings by $97M the other way.

The first half of 2026 supports that reading. Operating cash flow was $120.2M, up 6% on $113.3M, even after $32M of upfront licence fees paid in Q1. Q2 alone was $92.4M against $79.3M a year earlier, up 17%. Full-year consensus of $298M implies $178M in the second half, 24% below the $235M generated in the second half of 2025. The filings reviewed do not split the 2025 working-capital inflow by half, so how demanding that bar is remains partly unknown.

Operating Cash Flow Context

Total depreciation and amortization is not separately disclosed in the data set used here, so a CapEx/D&A ratio is omitted. The one non-cash charge that is known, intangibles amortization of $23.9M, has been flat for three years. The practical read is that GAAP net income understates cash generation by a stable amount, and the part that varies is working capital. For a fuller treatment of why the two measures diverge, see Free Cash Flow vs. Net Income.

Capital Expenditure Profile

Capital spending is effectively zero, which is why FCF margin tracks operating margin so closely. The flip side is that there is no capex lever to pull if revenue disappoints. Every point of margin pressure, from royalties, R&D or pricing, lands directly in free cash flow. Cost of products sold rose to 24.2% of revenue in Q2 2026 from 19.0% a year earlier on new Novitium royalties, a drag of about 5 points, or roughly $53M a year at the midpoint of revenue guidance.

FCF Quality Score: 6/10 (Medium Quality)

A 6/10 reflects cash generation that is cleaner than most of the screen and a revenue stream with a visible end date. The score sits at the top of the 5 to 6 range that a mixed-signal profile maps to, because five straight years of FCF at 99% or better of operating cash flow, a net-cash balance sheet and a 37% four-year FCF CAGR are hard to find together. What holds it below 7 is concentration: all of the cash comes from one drug with a dated patent position.

The strengths are mechanical. Conversion from operating cash flow to FCF is essentially complete, debt fell from $192M to $154M while cash and investments grew every year, and net cash of $809M equals 38% of the market capitalization. Net debt to EBITDA was -3.1x at the end of FY2025. SBC at 13% of FCF is a modest drag. None of this depends on financing or asset sales.

The considerations are about what is inside the number and what comes next. The $91.8M working-capital inflow, the unitemized $35.5M residual in 2025 operating cash flow and the cadence of licensing deals all mean the $348M headline overstates the repeatable level. Management also changed its capital-return message during 2026: a $150M buyback capacity cited in February gave way to language about "multiple transactions" in business development by August, and no 2026 repurchases appear in the 10-Qs reviewed. The finance seat has turned over twice this year, with a new CFO introduced in May, gone by July 16, and a controller now serving as interim principal financial officer. The CEO retires on December 31, with the COO moving into the role on January 1.

The structural risk is the patent calendar. Harmony settled with six of seven generic filers, with entry no earlier than March 2030 if it obtains pediatric exclusivity and September 2029 if it does not. The seventh filer, AET, went to bench trial in February 2026 and closing arguments were on October 22; the 30-month stay runs to February 2027, and a ruling and appeals are expected around then. A second suit on the amorphous-form patent could run 24 to 30 months plus appeals. Pediatric exclusivity depends in part on the TEMPO study, whose topline moved from the second half of 2026 to mid-2027. An adverse ruling could bring generic entry forward to 2027.

Forward Outlook: Key Scenarios

Two external variables drive the cash flow path: the outcome of the AET patent case and the date exclusivity ends, with growth in treated patients (about 8,950 on average in Q2 2026) setting the slope in between.

Scenario probabilities are illustrative judgement weights and do not constitute forecasts or price targets. Cash flow paths are assumptions anchored to consensus only for H2 2026 and FY2027E.

The base path runs $178M in H2 2026, $349M in 2027, $379M in 2028, $398M in 2029, $190M in 2030 and $50M in 2031. Discounted at 10%, base-case FCF has a present value of about $1.30B, which is 101% of the $1.31B enterprise value. The downside present value is about $521M and the upside about $1.62B. The range barely moves with the discount rate (the base case is about $1.26B at 12% and $1.34B at 8%) because most of the cash arrives within four years.

This is the point where a headline yield stops being a margin of safety. A 14% forward FCF yield looks wide against a 10% hurdle, but that comparison assumes the cash flow continues indefinitely. Undiscounted, base-case FCF repays today's enterprise value around the end of 2029, a few months before the March 2030 date. In effect the market is paying for the runway, and the pipeline is priced at close to zero. The scenarios leave out pipeline value, any new business development and interest income on the cash, and net cash is counted at face value.

Catalysts to Monitor

The patent ruling is the largest single variable. A decision on the AET bench trial is expected around the end of the 30-month stay in February 2027, and appeals would likely follow. A ruling or settlement that confirms a 2030 date would remove the downside scenario above. An adverse ruling, or an at-risk launch announcement, would make it the central case. Updates on whether the TEMPO delay affects the pediatric exclusivity timeline would also move the March 2030 date.

Second-half cash flow is the nearest checkable data point. Q3 results are due in early November, with consensus revenue near $274M, and the $178M of H2 operating cash flow implied by consensus is the figure to compare against. Guidance of $1.00B to $1.04B for 2026 revenue was reiterated on October 12 rather than raised after a quarter of 30% growth, and it implies second-half growth of 8% to 17%. Revenue per average patient, which dipped to $101K annualized in Q1 on seasonal plan resets and recovered to $117K in Q2, is the best read on gross-to-net pressure.

Cash deployment is the third. Management has framed business development as likely to involve several transactions, against a stated return bar of low-to-mid teens. Known cash calls include $10M of Novitium milestones, $25M due on USPTO approval under the MSN licence and up to $123M in development and regulatory milestones on the BP-205 sublicense. Pitolisant GR carries a PDUFA date of April 1, 2027, and BP-205 multiple-dose data is expected in the fourth quarter. A large deal at a full price, or one funded with debt or stock, would change the balance-sheet picture that supports the score.

Overall Assessment: HRMY FCF Quality Score 6/10

Harmony turns almost every operating dollar into free cash flow, and over FY2021 to FY2025 that cash stream grew from $98.3M to $347.9M with $809M of net cash now sitting behind it. The cash is real. The 16.4% trailing yield is not the right number to anchor on, though, because it counts a $91.8M working-capital inflow and applies to a stream that, in the base case, ends in 2030.

The multi-year pattern shows where the risk sits. FCF excluding working capital grew about 13% in 2025 and is projected to grow 18% a year through 2027E, yet the present value of base-case cash flows to the exclusivity date roughly equals the enterprise value, and the downside case is worth less than half of it. The unitemized operating cash flow residual and a pattern of annual deal spending argue for measuring against the $256M to $314M range rather than the headline. The score reflects both halves of that: very clean conversion, and a single-product patent calendar.

For a framework on weighing conversion, timing items and dilution, see Assessing FCF Quality. For how a yield like this one compares with sector benchmarks, see What Is a Good Free Cash Flow Yield?, and for the formula behind every FCF figure above, see How to Calculate Free Cash Flow. Other companies can be compared on the same basis in the FCF Screener.

⚠️ Disclaimer: This analysis is for educational and informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any recommendation to buy, sell, or hold any security. All financial data is sourced from publicly available SEC filings and is believed to be accurate as of the analysis date but has not been independently audited. Actual results may differ materially from any scenario estimates presented. FCF calculations use operating cash flow minus capital expenditures; alternative definitions may yield different results. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal.

Data Sources

• Harmony Biosciences Holdings, Inc. Annual Reports (10-K): FY2020–FY2025, SEC EDGAR XBRL (data.sec.gov); Q1 2026 and Q2 2026 Form 10-Q filings; Form 8-K and press release of October 12, 2026
• Harmony Biosciences earnings call transcripts (Q4 2025, Q1 2026, Q2 2026) and investor relations press releases
• Bloomberg Company Financials export (printed October 25, 2026) for adjusted net income, working capital, residual investing outflows and consensus FY2026E–FY2027E figures. XBRL cash of $753M excludes investments; the $882.5M cash and investments figure used in net cash comes from Bloomberg.
• Share price of $36.13 (October 23, 2026 close) from a secondary market-data source and not verified on a terminal; the discount rate and scenario weights are analyst assumptions